Physician profile
Robert B Stoltz
NPI 1043235310
$999.81
in general payments reported to CMS, 2019-2025
14 companies · $132 in 2025
The $132 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $78.06 · 2020: $244 · 2021: $171 · 2022: $213 · 2023: $81.34 · 2024: $80.03 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $293.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $293.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $382.37 | 2019-2025 | Ozempic, Rybelsus |
| Merz North America, INC. | $197.16 | 2020-2021 | |
| Antares Pharma, INC. | $133.44 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $110.01 | 2025 | Caplyta |
| Pfizer INC. | $32.80 | 2020-2021 | |
| Astellas Pharma US INC | $20.63 | 2024 | Izervay |
| Allergan, INC. | $18.99 | 2019 | |
| Avion Pharmaceuticals | $17.21 | 2023 | NP Thyroid 60 |
| Abbvie INC. | $15.49 | 2024 | |
| Glaxosmithkline, LLC. | $15.18 | 2021 | |
| Amgen INC. | $15.00 | 2019 | |
| Acella Pharmaceuticals, LLC | $14.87 | 2024 | NP Thyroid 60 |
| Tolmar, INC. | $13.93 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.73 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Stoltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.